Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q60156303)
Watch
English
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
scientific article published on 01 August 2006
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
title
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
main subject
zoledronic acid
1 reference
based on heuristic
inferred from title
prostate cancer
1 reference
based on heuristic
inferred from title
author
Dror Michaelson
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
Philip W. Kantoff
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
William K. Oh
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
author name string
Donald S Kaufman
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
Matthew R Smith
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
language of work or name
English
0 references
publication date
1 August 2006
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
published in
Cancer
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
volume
107
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
issue
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
page(s)
530-535
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
cites work
Cancer statistics, 2005
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Endothelin receptor antagonists in the treatment of prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Expression of endothelin receptor a associated with prostate cancer progression
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of bone metastasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.22043
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1002/CNCR.22043
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
PubMed publication ID
16804927
1 reference
stated in
Europe PubMed Central
PubMed publication ID
16804927
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16804927%20AND%20SRC:MED&resulttype=core&format=json
retrieved
26 December 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit